Based on the key indicators related to Allarity Therapeutics' liquidity, profitability, solvency, and operating efficiency, Allarity Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Allarity Therapeutics' Intangible Assets are relatively stable compared to the past year. Key indicators impacting Allarity Therapeutics' financial strength include:
Investors should never underestimate Allarity Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Allarity Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Allarity Therapeutics.
Net Income
(11.25 Million)
Allarity
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Sales Outstanding
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Investments
Change In Cash
Net Borrowings
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
Change To Netincome
Change To Liabilities
End Period Cash Flow
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Issuance Of Capital Stock
Sale Purchase Of Stock
Other Current Liab
Total Current Liabilities
Net Tangible Assets
Retained Earnings
Accounts Payable
Net Receivables
Inventory
Other Stockholder Equity
Total Current Assets
Common Stock
Property Plant Equipment
Other Liab
Total Assets
Short Long Term Debt Total
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Other Current Assets
Total Liab
Net Invested Capital
Long Term Investments
Property Plant And Equipment Gross
Short Long Term Debt
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Short Term Debt
Intangible Assets
Long Term Debt
Interest Expense
Ebit
Net Income Applicable To Common Shares
Income Tax Expense
Tax Provision
Net Interest Income
Interest Income
Depreciation And Amortization
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Cost Of Revenue
Probability Of Bankruptcy
Understanding current and past Allarity Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Allarity Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Allarity Therapeutics' assets may result in an increase in income on the income statement.
Allarity Therapeutics competes with Nuvalent, Arcellx, Vaxcyte, Crinetics Pharmaceuticals, and Cytokinetics. Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts. Allarity Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Allarity Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Allarity Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Allarity Therapeutics's current stock value. Our valuation model uses many indicators to compare Allarity Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Allarity Therapeutics competition to find correlations between indicators driving Allarity Therapeutics's intrinsic value. More Info.
Allarity Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Allarity Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Allarity Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Allarity Therapeutics Systematic Risk
Allarity Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Allarity Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Allarity Therapeutics correlated with the market. If Beta is less than 0 Allarity Therapeutics generally moves in the opposite direction as compared to the market. If Allarity Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Allarity Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Allarity Therapeutics is generally in the same direction as the market. If Beta > 1 Allarity Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Allarity Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Allarity Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Allarity Therapeutics growth as a starting point in their analysis.
Allarity Therapeutics January 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Allarity Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Allarity Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Allarity Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Allarity Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Allarity Therapeutics's daily price indicators and compare them against related drivers.
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.